Hep 3B2.1-7; Hepatocellular Carcinoma; Human (Homo sapiens) Item ID: ATCHB8064
| Permits and Restrictions |
View Permits |
|---|---|
| Organism | Homo sapiens, human |
| Tissue | Liver |
| Product Format | frozen |
| Morphology | epithelial |
| Culture Properties | adherent |
| Biosafety Level |
2 [Cells contain Hepatitis B]
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | hepatocellular carcinoma |
| Age | 8 years juvenile |
| Gender | male |
| Ethnicity | Black |
| Applications | This cell line is a suitable transfection host. |
| Storage Conditions | liquid nitrogen vapor phase |
| Disclosure | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Karyotype | modal number = 60 with a subtetraploid mode of 82; has a rearranged chromosome 1 (Knowles BB, Aden DP. Human hepatoma derived cell line, process for preparation thereof, and uses therefor. US Patent 4,393,133 dated Jul 12 1983) |
|---|---|
| Clinical Data | 8 years juvenile Black male |
| Genes Expressed | alpha fetoprotein (alpha-fetoprotein); hepatitis B surface antigen (HBsAg); albumin; alpha2 macroglobulin (alpha-2-macroglobulin); alpha1 antitrypsin (alpha-1-antitrypsin); transferrin;,alpha1 antichymotrypsin (alpha-1-antichymotrypsin); haptoglobin; ceruloplasmin; plasminogen; complement (C3, C4); C3 activator; fibrinogen; alpha1 acid glycoprotein (alpha-1 acid glycoprotein);,alpha2 HS glycoprotein (alpha-2-HS-glycoprotein); beta lipoprotein (beta-lipoprotein); retinol binding protein (retinol- |
| Cellular Products | Cellular products: alpha fetoprotein (alpha-fetoprotein); hepatitis B surface antigen (HBsAg); albumin; alpha2 macroglobulin (alpha-2-macroglobulin); alpha1 antitrypsin (alpha-1-antitrypsin); transferrin; (Knowles BB, Aden DP. Human hepatoma derived cell line, process for preparation thereof, and uses therefor. US Patent 4,393,133 dated Jul 12 1983) alpha1 antichymotrypsin (alpha-1-antichymotrypsin); haptoglobin; ceruloplasmin; plasminogen; complement (C3, C4); C3 activator; fibrinogen; alpha1 acid glycoprotein (alpha-1 acid glycoprotein); (Knowles BB, Aden DP. Human hepatoma derived cell line, process for preparation thereof, and uses therefor. US Patent 4,393,133 dated Jul 12 1983) alpha2 HS glycoprotein (alpha-2-HS-glycoprotein); beta lipoprotein (beta-lipoprotein); retinol binding protein (retinol-binding protein); Gc globulin (Knowles BB, Aden DP. Human hepatoma derived cell line, process for preparation thereof, and uses therefor. US Patent 4,393,133 dated Jul 12 1983) |
| Tumorigenic | Yes |
| Effects | Yes, forms tumors in nude mice |
| Comments | This line contains an integrated hepatitis B virus genome. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. |
|---|---|
| Subculturing | Remove medium, and rinse with 0.25% trypsin, 0.53 mM EDTA solution. Remove the solution and add an additional 1 to 2 mL of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37°C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. Corning® T-75 flasks (catalog #430641) are recommended for subculturing this product. Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended Medium Renewal: Twice per week |
| Cryopreservation | Freeze medium: Complete growth medium, 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Temperature: 37°CAtmosphere: air, 95%; carbon dioxide (CO2), 5% |
| STR Profile | Amelogenin: X CSF1PO: 8 D13S317: 12,14 D16S539: 10 D5S818: 13 D7S820: 8,10 THO1: 6,7 TPOX: 9 vWA: 17 |
|---|
| Name of Depositor | Wistar Institute |
|---|---|
| U.S. Patent Number | 4,393,133 |
| Disclosure | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| References |
Knowles BB, et al. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209: 497-499, 1980. PubMed: 6248960 Knowles BB, Aden DP. Human hepatoma derived cell line, process for preparation thereof, and uses therefor. US Patent 4,393,133 dated Jul 12 1983 Aden DP, et al. Controlled synthesis of HBsAg in a differentiated human liver carcinoma- derived cell line. Nature 282: 615-616, 1979. PubMed: 233137 Darlington GJ, et al. Growth and hepatospecific gene expression of human hepatoma cells in a defined medium. In Vitro Cell. Dev. Biol. 23: 349-354, 1987. PubMed: 3034851 Knowles BB, Aden DP. Human hepatoma derived cell line, process for preparation thereof, and uses therefor. US Patent 4,393,133 dated Jul 12 1983 |
| Permits |
These permits may be required for shipping this product to Australia:
|
|---|---|
| Basic Documentation | Product Sheet Certificate of Analysis SDS |
| References |
Knowles BB, et al. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209: 497-499, 1980. PubMed: 6248960 Knowles BB, Aden DP. Human hepatoma derived cell line, process for preparation thereof, and uses therefor. US Patent 4,393,133 dated Jul 12 1983 Aden DP, et al. Controlled synthesis of HBsAg in a differentiated human liver carcinoma- derived cell line. Nature 282: 615-616, 1979. PubMed: 233137 Darlington GJ, et al. Growth and hepatospecific gene expression of human hepatoma cells in a defined medium. In Vitro Cell. Dev. Biol. 23: 349-354, 1987. PubMed: 3034851 Knowles BB, Aden DP. Human hepatoma derived cell line, process for preparation thereof, and uses therefor. US Patent 4,393,133 dated Jul 12 1983 |